Table 2. Univariate analysis in the prediction of all-cause death within 5 years.
| Variable | HR | 95% CI | p-value |
|---|---|---|---|
| Age (per 1 year) | 1.058 | 1.047–1.068 | < 0.001 |
| Male sex | 0.983 | 0.805–1.199 | 0.863 |
| BMI (per 1 Kg/m2) | 0.909 | 0.883–0.937 | < 0.001 |
| DBP (per 1 mmHg) | 0.987 | 0.979–0.994 | 0.001 |
| NYHA Fc IV | 1.796 | 1.327–2.432 | < 0.001 |
| Hypertension | 1.338 | 1.090–1.642 | 0.005 |
| Diabetes mellitus | 1.401 | 1.142–1.720 | 0.001 |
| Ischemic heart disease | 1.344 | 1.088–1.661 | 0.006 |
| Creatinine (per 1 mg/dL) | 1.052 | 1.019–1.085 | 0.001 |
| Total cholesterol (per 1 mg/dL) | 0.995 | 0.993–0.998 | < 0.001 |
| LVEDD (per 1 mm) | 0.985 | 0.974–0.997 | 0.011 |
| LVEDV (per 1 mL) | 0.998 | 0.996–1.000 | 0.063 |
| LA diameter (per 1 mm) | 1.020 | 1.008–1.031 | 0.001 |
| LAGLS (per 1%) | 0.979 | 0.968–0.991 | 0.001 |
| E/E′ ratio (per 1) | 1.017 | 1.003–1.030 | 0.014 |
| PASP (per 1mmHg) | 1.019 | 1.012–1.026 | < 0.001 |
| TAPSE (per 1mm increase) | 0.977 | 0.957–0.999 | 0.037 |
| TAPSE/PASP ratio | 0.219 | 0.118–0.406 | < 0.001 |
| Use of RAS-inhibitors at discharge | 0.690 | 0.554–0.861 | 0.001 |
| Use of beta-blockers at discharge | 0.728 | 0.578–0.916 | 0.007 |
BMI: body mass index, CI: confidence interval, DBP: diastolic blood pressure, HR: hazard ratio, NYHA Fc: New York Heart Association functional class, LA: left atrium, LAGLS: left atrial global longitudinal strain, LVEDD: left ventricular end-diastolic dimension, LVEDV: left ventricular end-diastolic volume, PASP: pulmonary artery systolic pressure, RAS: renin-angiotensin system, TAPSE: tricuspid annular plane systolic excursion.